Study of STLX-2012 in Healthy Volunteers

The purpose of this research is to establish the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single IV dose of STLX-2012.

Inclusion Criteria: * Male or female participants aged 18-55 years old, inclusive, at Screening. * Body mass index of 18-32 kg/m\^2, inclusive * Healthy as determined by the investigator * Adequate hepatic and renal function * Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures * Male participants and females of childbearing potential must agree to use an effective method of contraception for 30 days after the last dose of STLX-2012 Exclusion Criteria: * Pregnant or lactating female. * Positive urine drug screen or alcohol breath test * Neutropenia, defined as neutrophil count \<2.0 x 10\^9/L * History of allergic reaction requiring treatment or anaphylactic reactions to any therapeutic drug. * Previous treatment with an IL-1RAP monoclonal antibody * History of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, inflammatory, or allergic disease (excluding mild seasonal allergies)